Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $8.3652W HIGH $28.00
Volume
735.60 K
Value Traded
14.03 M
Short % Float
20.15%
+2.27%Week
-24.82%1 Month
-32.44%3 Month
-22.17%6 Month
-97.73%5 Year
-97.73%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
915.17 M
EPS (TTM)
-2.97
P/E Ratio
-
Ent. Value
453.96 M
Total Shares
63.60 M
Float Shares
54.50 M
Insiders
14.30%
Institutions
102.32%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
JBIO Catalyst Timeline
Dated clinical, regulatory and corporate events for Jade Biosciences, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Jade Biosciences, Inc.
173Total events
15Upcoming
30Tier-1 (high impact)
2020 to 2028Coverage
Upcoming catalysts 2
Event history 50
●Poster PresentationJADE301Presentation
JADE301 preclinical data e-poster presented at EADV 2026 (Poster #P1813)
dermatomyositissource ↗
▲Preclinical PoCJADE301Preclinical
Preclinical data characterizing JADE301 presented at EADV 2026
dermatomyositissource ↗
▲Interim AnalysisJADE101Trial
Positive interim Phase 1 data for JADE101 announced
IgA nephropathysource ↗
▲Oral PresentationJADE101Presentation
Phase 1 JADE101 data presented at 63rd ERA Congress
IgA nephropathysource ↗
▲Trial InitiationJADE101Trial
Dosing began in Phase 2 JUNIPER trial of JADE101
IgA nephropathysource ↗
●Poster PresentationJADE101Presentation
JUNIPER Trial-in-Progress update presented at ERA Congress
IgA nephropathysource ↗
▲Trial InitiationJADE201Trial
Dosing began in Phase 1 trial of JADE201 in rheumatoid arthritis
rheumatoid arthritissource ↗
▼Equity OfferingCorporate
Closed public offering of 11,500,000 shares at $15.00 per share, gross proceeds $172.5 million
◆Oral PresentationJADE101Presentation
Oral presentation at ERA 2026: Interim Phase 1 results
IgA nephropathysource ↗
◆Oral PresentationJADE101Presentation
Oral presentation at ERA 2026: Phase 2 JUNIPER trial design
IgA nephropathysource ↗
◆Equity OfferingCorporate
Jade Biosciences announces proposed underwritten public offering of common stock and pre-funded warrants
◆Oral PresentationJADE101Presentation
Conference call to discuss interim Phase 1 healthy volunteer results for JADE101
IgA nephropathysource ↗
▲First Patient DosedJADE-001Trial
First-in-human healthy volunteer data expected
IgA nephropathysource ↗
▲First Patient DosedJADE201Trial
First participant dosed in first-in-human Phase 1 trial of JADE201
rheumatoid arthritissource ↗
▲First Patient DosedJADE101Trial
First participant dosed in Phase 2 JUNIPER trial of JADE101 in IgAN
IgA nephropathysource ↗
◆Oral PresentationJADE101Presentation
Biomarker-rich interim Phase 1 data for JADE101 to be presented in oral session at ERA Congress
IgA nephropathysource ↗
◆Management ChangeCorporate
Promotion of Dr. Andrew King to President, Research and Development
◆Interim AnalysisJADE101Trial
JADE101 Phase 1 healthy volunteer interim data expected
IgA nephropathysource ↗
◆Trial InitiationJADE101Trial
Initiation of JADE101 Phase 2 clinical trial in IgA nephropathy
IgA nephropathysource ↗
◆First Patient DosedJADE201Trial
First-in-human dosing for JADE201 Phase 1 clinical trial
rheumatoid arthritissource ↗
◆Trial InitiationJADE201Trial
Phase 1 trial of JADE201 in RA expected to begin in Q2 2026
rheumatoid arthritissource ↗
◆Oral PresentationPresentation
Jade Biosciences management to host presentations at upcoming conferences
◆Oral PresentationPresentation
Jade Biosciences presentation at 44th Annual J.P. Morgan Healthcare Conference
◆Interim AnalysisJADE101Trial
Interim data from Phase 1 healthy volunteer trial expected
immunoglobulin A nephropathy (IgAN)source ↗
◆Topline ReadoutJADE101Clinical Data
Interim data from Phase 1 healthy volunteer trial of JADE101
immunoglobulin A nephropathy (IgAN)source ↗
◆Trial InitiationJADE201Trial
Initiate first-in-human study of JADE201 in rheumatoid arthritis
rheumatoid arthritissource ↗
▲Oral PresentationJADE101Presentation
Presented preclinical safety and translational data at ASN Kidney Week
IgA nephropathy (IgAN)source ↗
▲Development Candidate NominationJADE201Preclinical
Introduced second development candidate JADE201
autoimmune diseasessource ↗
◆Poster PresentationJADE101Presentation
Translational Modeling of Biomarker Responses to APRIL Inhibition presented at ASN Kidney Week 2025
immunoglobulin A nephropathy (IgAN)source ↗
▲First Patient DosedJADE101Trial
First patient dosed in Phase 1 trial of JADE101 for IgA nephropathy
IgA nephropathysource ↗
Past FDA Catalysts and PDUFA Decisions
How JBIO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | JADE301 | Pre-clinical data readout | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D38 / 100
Pipeline Score
$291M
Pipeline Value
Overvalued
Valuation Signal
2
Drugs Scored
0.3x
rNPV / MCap
Top 44%
Micro Cap(rank 291 of 660)
Percentile Rank
Jade Biosciences, Inc. faces pipeline headwinds (38/100), with $728M risk-adjusted pipeline value, led by JADE101 in IgA Nephropathy (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| JADE101 Small moleculeNCT07541287 | IgA Nephropathy | Phase 2 | RECRUITING | 30 | Apr 1, 2029 |
Clinical Trial Results
Readouts, endpoints and source filings for every JBIO program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| JADE101 | IgA nephropathy | Phase 1 | 2026-08-10 | Mean IgA reductions reached approximately 70% from baseline after a single 700 mg dose.; Greater than 70% IgA reductions simulated at steady state with a single 350 mg subcutaneous maintenance injection every 12 weeks following one 700 mg induction dose.Read More | Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Eisner MarkDirector | Grant/Award | 47,675 47,675 held | $0.00 | 06/25/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in JBIO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Fairmount Funds Management LLC | 6.7 % (45.7 %) | 101.18 M | 4.55 M |
JBIO Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How JBIO ranks across every disease it competes in
Competitive Position is a premium feature
See how JBIO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialJBIO News
JBIOJade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026
Jade Biosciences has announced promising preclinical data for JADE301, an anti-IFN-β monoclonal antibody aimed at treating dermatomyositis. The data, presented at the EADV Congress, indicates that JADE301 has a high affinity for its target and a significantly extended half-life, supporting its potential for infrequent dosing. A Phase 1 trial is expected to begin in late 2026.
Read more →JBIOJade Biosciences to Participate in Upcoming Conferences
Jade Biosciences, a clinical-stage biotechnology company, announced its participation in several upcoming conferences, including the Wells Fargo Healthcare Conference and the Citi Biopharma Summit. The management team will also hold one-on-one investor meetings. The company focuses on developing therapies for autoimmune diseases, with its lead candidate currently under evaluation.
Read more →JBIOJade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Jade Biosciences reported positive interim Phase 1 results for its drug JADE101, indicating potential for effective treatment in IgA nephropathy. The company is advancing its clinical trials, with a Phase 2 trial underway and a Phase 3 trial expected to begin in 2027. Financially, Jade holds $461 million in cash, providing a solid runway into 2028 despite a net loss of $55.8 million in Q2 2026.
Read more →JBIOJade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
Jade Biosciences has appointed Dr. Mark Eisner to its Board of Directors, effective June 25, 2026. Dr. Eisner, with over 25 years of experience in clinical development and immunology, is expected to enhance the company's capabilities in advancing its antibody-based therapies for autoimmune diseases. His previous roles include leadership positions at Vir Biotechnology and Genentech.
Read more →JBIOJade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Jade Biosciences has successfully closed a public offering of 11.5 million shares, raising $172.5 million. The offering included a full exercise of the underwriters' option to purchase additional shares. The company plans to use the proceeds to fund clinical trials and research activities. Jefferies, TD Cowen, and UBS Investment Bank managed the offering.
Read more →JBIOJade Biosciences Announces Pricing of Public Offering of Common Stock
Jade Biosciences has announced the pricing of a public offering of 10 million shares at $15.00 each, aiming to raise $150 million. The proceeds will fund clinical trials and research activities. The offering is expected to close on June 5, 2026, pending customary conditions. The company is focused on therapies for autoimmune diseases.
Read more →JBIOJade Biosciences Announces Proposed Underwritten Public Offering
Jade Biosciences, a clinical-stage biotechnology company, announced its intention to conduct an underwritten public offering of common stock and pre-funded warrants. The proceeds will support clinical trials and R&D efforts. The offering is subject to market conditions, and there is no guarantee of completion or specific terms. Jefferies, TD Cowen, and UBS are managing the offering.
Read more →JBIO▼ -11.6%on this newsshared move
JADE101 Phase 1 Interim Data
Jade Therapeutics presented interim data on its JADE101 Phase 1 study, highlighting that it has met objectives and demonstrated a favorable safety profile. The data suggests the potential for every-12-week subcutaneous dosing with significant IgA reduction. However, the company cautioned that interim results are not necessarily indicative of final outcomes and that various risks could impede future clinical trials and regulatory approvals.
Read more →JBIO▼ -11.6%on this newsshared move
Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy
Jade Biosciences announced positive interim results from its Phase 1 trial of JADE101, an investigational treatment for IgA nephropathy. The trial showed significant IgA reductions sustained at 12 weeks, with a favorable safety profile. The company plans to advance to Phase 2 and initiate a Phase 3 trial in 2027, aiming for best-in-class status in treatment.
Read more →JBIOJade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy
Jade Biosciences announced a conference call on June 1, 2026, to discuss interim results from its Phase 1 study of JADE101, a monoclonal antibody for IgA nephropathy. The results are expected to inform dosing strategies and clinical profiles. JADE101 aims to be a best-in-class treatment for this autoimmune kidney disease.
Read more →JBIOJade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy
Jade Biosciences has announced the dosing of the first participant in its Phase 2 JUNIPER clinical trial for JADE101, aimed at treating immunoglobulin A nephropathy (IgAN). The trial will assess safety, tolerability, and efficacy in approximately 30 participants. Interim data is anticipated in 2027, showcasing the potential of JADE101 as a treatment option.
Read more →JBIOJade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody
Jade Biosciences has initiated a Phase 1 clinical trial for JADE201, a novel monoclonal antibody targeting BAFF-R to treat autoimmune diseases. The first participant has been dosed, with interim data expected in 2027. JADE201 aims to enhance B cell depletion while allowing for less frequent dosing, addressing limitations of existing therapies.
Read more →JBIOJade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
Jade Biosciences reported its Q1 2026 financial results, highlighting upcoming clinical trials for its lead candidate, JADE101, and the initiation of JADE201. The company has a robust cash position of $311 million, expected to sustain operations until mid-2028. However, it also reported a net loss of $40.4 million due to increased R&D expenses.
Read more →JBIOJade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jade Biosciences has appointed Dr. Edward R. Conner as Chief Medical Officer, granting him 500,000 stock options under the Inducement Plan. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and aims to attract talent to the company. Jade focuses on innovative therapies for autoimmune diseases, including its lead candidate, JADE101.
Read more →JBIO▲ +10.3%on this newsshared move
Jade Biosciences Appoints Edward R. Conner, M.D., as Chief Medical Officer
Jade Biosciences has appointed Dr. Edward R. Conner as Chief Medical Officer, effective immediately. Dr. Conner brings extensive experience in clinical development and regulatory strategy, which will aid in advancing the company's pipeline of therapies for autoimmune diseases. The company is preparing for key milestones, including Phase 1 data for JADE101 and a Phase 2 trial in IgA nephropathy.
Read more →JBIOJade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Jade Biosciences reported its financial results for Q4 and full year 2025, highlighting a strong cash position and advancements in its clinical pipeline. The company expects to initiate several clinical trials in 2026, including JADE101 for IgA nephropathy and JADE201 for rheumatoid arthritis. Despite a rising net loss, Jade is well-positioned for future growth with a focus on best-in-class therapies for autoimmune diseases.
Read more →JBIO▼ -7.3%on this news
Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference
Jade Biosciences has outlined its strategic priorities for 2026, focusing on advancing its pipeline of monoclonal antibodies for autoimmune diseases. The company anticipates key milestones for its lead candidate, JADE101, in IgA nephropathy, and plans to initiate Phase 2 trials. Jade's strong financial position is expected to support operations into 2028, positioning the company for growth.
Read more →JBIOJade Biosciences Announces $45 Million Private Placement
Jade Biosciences has announced a private placement financing agreement with BB Biotech, expected to yield approximately $45 million. The funds will be utilized for research and development, corporate expenses, and working capital. The private placement involves the sale of over 3 million shares at $14 each, set to close around December 16, 2025.
Read more →About Jade Biosciences, Inc.
Headquarters221 CRESCENT ST., WALTHAM, MA, 02453
BIOPHARMAWATCH ELITE PLUS
Trade the next JBIO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime